Autopsy report · NCT03969446

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

“Accrual goal Met”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year before it started.
• Suspended: paused, and may or may not restart.
• 54 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Phase 1

Sponsor

City of Hope Medical Center

Sponsor type

University, hospital or other

Conditions

Acute Myeloid Leukemia; Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Myelodysplastic Syndrome

Interventions

Decitabine; Pembrolizumab; Venetoclax

Participants

54 (planned, not actual)

Sites

1

Countries

United States

Trials that died the same way

• Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia
  “Unable to meet accrual goals” (75% match in meaning)
• Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme
  “No accrual” (70% match in meaning)
• Afatinib in Advanced Refractory Urothelial Cancer
  “Unable to meet accrual goal after several years” (68% match in meaning)
• Patient Preferences in Making Treatment Decisions in Patients With Stage I-IVA Oropharyngeal Cancer
  “Poor accrual” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.